Emisphere Technologies, Inc. (OTCBB: EMIS), a commercial stage, specialty pharmaceutical company, is currently preparing to launch its first prescription product, oral Eligen B12, in the United States. Beyond Eligen B12, the company employs its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere is also currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, visit the company’s website at www.emisphere.com.